Clinical trials: Tumor-Induced Osteomalacia
Tumor-induced Osteomalacia (TIO)
Tumor-induced Osteomalacia Disease Monitoring Program
The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the…
- Trial name
- NCT04783428
- Testing
- No intervention
- Where
- 6 sites in United States, Argentina
- Volunteers
- 23 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
X-linked Hypophosphatemia, Tumor-Induced Osteomalacia
Expanded Access to Burosumab
Individual patient expanded access requests may be considered for patients who have no other treatment options
- Trial name
- NCT03775187
- Testing
- Burosumab
- Sponsor
- Kyowa Kirin Co., Ltd.
Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Before switching to the post-marketing study: To evaluate the efficacy and safety of KRN23 after its 144-week once every 4 weeks (Q4W) repeated SC administration to Japanese and Korean patients with TIO or ENS by a multicenter…
- Trial name
- NCT02722798
- Testing
- KRN23
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 14 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS)
Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
The primary objectives of this study are to evaluate the effect of burosumab treatment on: Increasing serum phosphorus levels in adults with TIO or ENS-associated osteomalacia Improvement in TIO/ENS-associated osteomalacia as…
- Trial name
- NCT02304367
- Testing
- Burosumab
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kyowa Kirin, Inc.
Tumor-Induced Osteomalacia (TIO)
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with TIO
- Trial name
- NCT05357573
- Testing
- KRN23
- Where
- 3 sites in China
- Volunteers
- 9 people
- Sponsor
- Kyowa Kirin Co., Ltd.